Press Releases

Retinal Vein Occlusion Market Value, Volume, Growth Predictions, and Forecast to 2022-2030

Share This Article

Telehealth Services Help Revive Market Growth During COVID-19 Pandemic

Stakeholders in the retinal vein occlusion market are under scrutiny to provide efficient care and support to patients during the ongoing COVID-19 pandemic. Pharmaceutical companies are boosting their production capabilities to ensure the robust supply of drugs and therapeutics in hospitals, clinics, and emergency settings. As such, the pandemic has compelled patients to delay or cancel their treatment, which is affecting the sales of therapeutics. Nevertheless, telehealth services and mobile apps are helping to revive the growth of the retinal vein occlusion market.

Get the sample copy of report@ https://qyresearchmedical.com/sample/111792

An increasing number of individuals are opting for remote health services. This has led to the demand for telehealth services and mobile apps during the ongoing pandemic. Mass vaccination programs are anticipated to boost the revenue flow in the global economy.

Full Ophthalmologic Examination, VA Measurement Necessary to Improve Patient Outcomes

The retinal vein occlusion market is expected to surpass US$ 32.5 Bn by 2031. However, there is a need for full ophthalmologic examination when retinal vein occlusion (RVO) is suspected, along with a VA (Visual Acuity) measurement in order to improve patient outcomes. There is increased awareness about iris examination to rule out neovascularization.

In order to improve clinical numbers, healthcare providers are taking into consideration the medical history and paying attention to examinations carried out for achieving efficient diagnosis of RVO. The presence of macular edema (ME) and the extent of retinal ischemia are being evaluated. Healthcare companies are gaining awareness that long-term monitoring of patients should be individualized to combine maintenance with practicability. While steroids may be considered in patients with systemic cardiovascular risk, surgery is advisable only for few and specific patient cases.

Ranibizumab Gains Prominence in U.S., Indian Healthcare Systems for RVO Treatment

Retinal vein occlusion is the second-most common retinal vascular disease, which can potentially lead to loss of vision. Since ranibizumab is approved by the U.S. Food and Drug Administration (USFDA) for the treatment of ME secondary to RVO. This is benefitting stakeholders in the India retinal vein occlusion market since the Drug Controller General of India (DCGI) has also approved ranibizumab for the treatment of macular edema caused by retinal vein occlusion.

Large, randomized, and controlled clinical trials are substantiating the efficacy of anti-VEGF (vascular endothelial cell growth factor) agents, including ranibizumab for the treatment of ME secondary to RVO. Such findings are translating into revenue opportunities for companies in the retinal vein occlusion market. Ranibizumab for the treatment of ME caused by branch retinal vein occlusion (BRVO) showed rapid and sustained visual improvement in patients who received monthly intravitreal injections of the drug.

Intravitreal Injections of VEGF Inhibitors Result in Better Visual, Anatomic Outcomes

The high prevalence of cardiovascular and other systemic diseases in Nepal is contributing to the growth of the Nepal retinal vein occlusion market. Treatment options such as laser photocoagulation and intravitreal injections of either VEGF inhibitors or steroids are being publicized. It has been found that intravitreal injections of VEGF inhibitors for RVO result in good visual and anatomic outcomes as compared to macular laser photocoagulation or intravitreal injections of triamcinolone.

Companies in the retinal vein occlusion market are increasing their production capabilities in VEGF inhibitors that are gaining popularity as the preferred first line agents in the treatment of RVO. It has been found that the choice of VEGF inhibitors among countries varies as per their drug regulatory processes.

Laser Coagulation May Effectively Improve Visual Prognosis in BRVO Patients

The retinal vein occlusion market is slated to clock a favorable CAGR of 7.3% during the forecast period. In order to properly diagnose BRVO, there is a need for specialized tests such as fluorescein angiography, ocular coherence tomography (OCT), and color fundus photography. Apart from preventive care, clinicians are relying on laser therapy to help manage the symptoms of branch retinal vein occlusion.

It has been found that laser coagulation could effectively improve visual prognosis in patients with BRVO during three years of follow-up. Such trends are contributing to the growth of the global retinal vein occlusion market. It has been found that multiple laser treatments are required to achieve the desired results in patients. VitreoRetinal Surgery, PLLC – a provider of advanced retinal care in Minessota, is gaining recognition for offering laser treatment to BRVO patients.

Different Treatment Modalities Improve Clinical Numbers

Companies in the retinal vein occlusion market are increasing their output capacities in corticosteroid drugs that help to combat the inflammatory components, which lead to edema. On the other hand, healthcare professionals are acquiring proficiency in the focal laser therapy. This treatment provides lasers to areas of swelling to cause a reduction in edema.

Stakeholders in the retinal vein occlusion market are increasing their research in the pan-retinal photocoagulation therapy. This treatment is used when patients have new blood vessel formation following the retinal vein occlusion. On the other hand, anti-vascular endothelial growth factor (anti-VEGF) medications such as Lucentis, Avastin, and Eylea are being used in cases of BRVO where neovascularization or macular edema is present. These medications are directly injected in the eye and help inhibit abnormal blood vessels from growing.

Laser Photocoagulation Treatment Reduce Severity of Retinal Neovascularization

One of the serious problems in BRVO is that of retinal neovascularization. In advanced cases, abnormal blood vessels grow from the retina into the vitreous gel of the eye. Since these vessels are very fragile, this can lead to major bleeding, also known as vitreous hemorrhage, and scar tissue formation. Hence, healthcare providers in the retinal vein occlusion market are increasing the availability of the laser photocoagulation treatment to the peripheral retina, which is found to be very helpful in this situation.

Laser treatment usually results in stabilization or even regression of the blood vessel growth. The bleeding caused due to retinal neovascularization may sometimes clear on its own but in a few cases will require the need for operation to remove the blood and the vitreous gel.

View full report@ https://qyresearchmedical.com/report/retinal-vein-occlusion-market-type-central-retinal-vein-occlusion-and-branch-retinal-vein-occlusion-and-treatment-type-anti-vegf-drugs-corticosteroid-drugs-pan-retinal-photocoagulation-therapy-and-laser-thera-2021-2030/111792

Analysts’ Viewpoint

Telehealth services and mobile apps are encouraging individuals to seek professional treatment in cases where the severity of RVO is high amid the ongoing COVID-19 outbreak. OCT, ophthalmoscopy, and fluorescein angiography are helping in effective diagnosis of RVO. However, there is still a need for taking into consideration the medical history of patients while evaluating the treatment options for central retinal vein occlusion. Hence, stakeholders in the retinal vein occlusion market should work closely with medical practitioners to gain awareness about any risk factors that raise suspicion for a vein occlusion. Such efforts will help improve therapeutics and better patient outcomes.

Retinal Vein Occlusion Market: Overview

This report analyzes the current scenario and future prospects of the global retinal vein occlusion market. Retinal vein occlusion is the blockage of the retinal vein due to blood clot. Retinal vein occlusion is the second most common cause of visual impairment globally. A blood clot causes a blockage in the vein, which starts draining blood from retina, resulting in swelling and bleeding, affecting the vision of the person. Rise in prevalence of eye diseases globally, increase in geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments are the major drivers of the global retinal vein occlusion market.

The report includes an elaborate executive summary, which provides a snapshot of various segments of the global retinal vein occlusion market. It also provides information and data analysis of the global retinal vein occlusion market about segments based on type, treatment type, and region.

The overview section of the report provides a detailed qualitative analysis of drivers, restraints, and opportunities that affect the global retinal vein occlusion market

The report includes company profiles, which provide information about their business, product portfolios, strategic overview, and competition landscape in the global retinal vein occlusion market

The report on the global retinal vein occlusion market offers market attractiveness analysis of regions and segments

The last section of the report comprises quantitative and qualitative analyses on market share/position of key players operating in the global retinal vein occlusion market. It analyzes key competitive strategies adopted by major industry players, thereby presenting a thorough understanding of the competitive scenario in the global retinal vein occlusion market.

Retinal Vein Occlusion Market: Key Segments

In terms of type, the global retinal vein occlusion market has been bifurcated into central retinal vein occlusion and branch retinal vein occlusion. The central retinal vein occlusion segment dominated the global retinal vein occlusion market in 2020, and the trend is projected to continue during the forecast period.

Based on treatment type, the global retinal vein occlusion market has been classified into anti-VEGF drugs, corticosteroid drugs, pan-retinal photocoagulation therapy, and laser therapy. The anti-VEGF drugs segment held major share of the global retinal vein occlusion market in 2020. Rise in prevalence and incidence of diabetes drives the segment.

Market size and forecast for each of these segments and sub-segments have been provided from 2017 to 2031. The CAGR of respective segment has also been provided from 2021 to 2031, considering 2020 as the base year, and 2017, 2018, and 2019 as historical years.

Retinal Vein Occlusion Market: Regional Outlook

The global retinal vein occlusion market report provides size and forecast for each region and country/sub-region from 2017 to 2031. The CAGR for each of these regions and countries has also been provided for the forecast period from 2021 to 2031. The retinal vein occlusion market study also covers the competitive scenario in these regions.

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111792/2900

Retinal Vein Occlusion Market Players

Key players in the global retinal vein occlusion market have been profiled based on attributes such as company overview, product portfolio, financial overview, strategic overview, recent developments, and competitive business strategies

Key Questions Answered in Retinal Vein Occlusion Market Report

  • What are the major drivers, restraints, and opportunities in the market?
  • What are the revenue share projections of key segments of the global retinal vein occlusion market during the forecast period?
  • Which segment is likely to lead the global retinal vein occlusion market in terms of revenue by 2031?
  • How technological developments are widening the scope for the global retinal vein occlusion market?
  • What is the market position of different companies operating in the global retinal vein occlusion market?

Retinal Vein Occlusion Market – Segmentation

Type

  • Central Retinal Vein Occlusion
  • Branch Retinal Vein Occlusion

Treatment Type

  • Anti-VEGF Drugs
  • Corticosteroid Drugs
  • Pan-retinal Photocoagulation Therapy
  • Laser Therapy

Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

TABLE OF CONTENT

1. Preface

1.1. Market Definition and Scope

1.2. Market Segmentation

1.3. Key Research Objectives

1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Retinal Vein Occlusion Market

4. Market Overview

4.1. Introduction

4.1.1. Type Definition

4.1.2. Industry Evolution / Developments

4.2. Overview

4.3. Market Dynamics

4.3.1. Drivers

4.3.2. Restraints

4.3.3. Opportunities

4.4. Global Retinal Vein Occlusion Market Analysis and Forecast, 2017–2030

4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insights

5.1. Key Industry Events

5.2. COVID-19 Pandemic Impact on Industry (value chain and short-/ mid-/ long-term impact)

6. Global Retinal Vein Occlusion Market Analysis and Forecast, by Type

6.1. Introduction & Definition

6.2. Key Findings / Developments

6.3. Market Value Forecast by Type, 2017–2030

6.3.1. Central Retinal Vein Occlusion

6.3.2. Branch Retinal Vein Occlusion

6.4. Market Attractiveness Analysis, by Type

7. Global Retinal Vein Occlusion Market Analysis and Forecast, by Treatment Type

7.1. Introduction & Definition

7.2. Key Findings / Developments

7.3. Market Value Forecast, by Treatment Type, 2017–2030

7.3.1. Anti-VEGF Drugs

7.3.2. Corticosteroid Drugs

7.3.3. Pan-retinal Photocoagulation Therapy

7.3.4. Laser Therapy

7.4. Market Attractiveness Analysis, by Treatment Type

8. Global Retinal Vein Occlusion Market Analysis and Forecast, by Region

8.1. Key Findings

8.2. Market Value Forecast, by Region

8.2.1. North America

8.2.2. Europe

8.2.3. Asia

8.2.4. Latin America

8.2.5. Middle East & Africa

8.3. Market Attractiveness Analysis, by Country/Sub-region/Region

9. North America Retinal Vein Occlusion Market Analysis and Forecast

9.1. Introduction

9.1.1. Key Findings

9.2. Market Value Forecast, by Type, 2017–2030

9.2.1. Central Retinal Vein Occlusion

9.2.2. Branch Retinal Vein Occlusion

9.3. Market Value Forecast, by Treatment Type, 2017–2030

9.3.1. Anti-VEGF Drugs

9.3.2. Corticosteroid Drugs

9.3.3. Pan-retinal Photocoagulation Therapy

9.3.4. Laser Therapy

9.4. Market Value Forecast, by Country, 2017–2030

9.4.1. U.S.

9.4.2. Canada

9.5. Market Attractiveness Analysis

9.5.1. By Type

9.5.2. By Treatment Type

9.5.3. By Country

10. Europe Retinal Vein Occlusion Market Analysis and Forecast

……..

Purchase Complete Report Now@ https://qyresearchmedical.com/report/checkout/111792/2900

You can place an order or ask any questions, please feel free to contact sales@qyresearchmedical.com | +1 9197 992 333

About Us

QYResearch Medical, focuses on custom research, management consulting, IPO consulting, industry chain research, and data base & seminar services. The company owns large basic databases (such as National Bureau of Statistics Database, Customs Import and Export Database, Industry Association Database, etc.), expert resources (including industry experts who own more than 10 years experiences on marketing or R&D in industries of healthcare services, medical technology & devices, etc.), professional survey team (the team members obtained more than 3 years market survey experience and more than 2 years deep expert interview experience), and excellent data analysis team (SPSS statistics and PPT graphics process team).

QYResearch Medical has more than 4000 global well-known customers, covering more than 30 industries including pharmaceuticals, medical technology & devices, healthcare services etc. Company services cover one-stop solution as Data-Analysis-Suggestion-Consulting Implementation. Research regions cover China, US, EU, Asia, Middle East and Africa, South America, Australia, and other regions in the world.

For Latest Update Follow Us:

https://www.linkedin.com/company/qyresearch-medical/

https://www.facebook.com/QYResearch-Medical-108186514228917/

https://twitter.com/qyresearchmedi

Show More

Related Articles

Back to top button